Abnormally High Parathyroid Hormone Levels Worsens Outcomes in Vitamin D Depleted Critical Care Patients
Clinical Deterioration Caused by Elevated Parathyroid Hormone Levels Among Critically-Ill Patients With Vitamin D Depletion: a Secondary Analysis of a Multicenter, Prospective, Observational Study
1 other identifier
observational
320
1 country
1
Brief Summary
This study aims to investigate the impacts of abnormally elevated PTH levels on clinical outcomes among critically ill patients with vitamin D depletion.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 21, 2024
CompletedFirst Submitted
Initial submission to the registry
November 24, 2024
CompletedFirst Posted
Study publicly available on registry
December 2, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2024
CompletedDecember 2, 2024
May 1, 2024
7 months
November 24, 2024
November 27, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Mortality
Survival on day 28, survival to hospital discharge
From enrollment to day 90
Secondary Outcomes (4)
Acute Physiology and Chronic Health Evaluation II (APACHE II) score
From enrollment to day 90
Sequential Organ Failure Assessment (SOFA) score
From enrollment to day 90
ICU length of stay
From enrollment to day 90
Laboratory parameters
From enrollment to day 90
Eligibility Criteria
Critically ill patient
You may qualify if:
- \. Critically ill patients within 48 hours of ICU admission
You may not qualify if:
- Less than 20 years old
- Severe malnutrition (BMI\<18kg/m2)
- Severe anemia (hemoglobin concentration \<7g/dL)
- Receiving high-dose vitamin D treatment (\> 3000 IU/day) within four weeks
- Have been admitted to the ICU within three months
- Suffering from diseases that affect vitamin D concentration, calcium metabolism or bone metabolism (for example: parathyroid disease, rickets, chirtosis, and severe cirrhosis \[Child C\])
- Patients and family members who do not speak the native language
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Taiwan University Hospital
Taipei, 100, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 24, 2024
First Posted
December 2, 2024
Study Start
May 21, 2024
Primary Completion
December 31, 2024
Study Completion
December 31, 2024
Last Updated
December 2, 2024
Record last verified: 2024-05
Data Sharing
- IPD Sharing
- Will not share